165 related articles for article (PubMed ID: 35237257)
21. Selinexor With Anti-PD-1 Antibody as a Potentially Effective Regimen for Patients With Natural Killer/T-Cell Lymphoma Failing Prior L-Asparaginase and PD-1 Blockade.
Tao R; Liu C; Zhang W; Zhu Y; Ma Y; Hao S
Oncologist; 2024 Jan; 29(1):e90-e96. PubMed ID: 37616529
[TBL] [Abstract][Full Text] [Related]
22. Radiotherapy followed by DICEP regimen in treatment of newly diagnosed, stage IE/IIE, extranodal NK/T-cell lymphoma patients.
Liu Y; Xue K; Xia Z; Jin J; Wang J; Sun H; Lv F; Liu X; Cao J; Hong X; Guo Y; Ma X; Zhang Q
Cancer Med; 2020 Aug; 9(15):5400-5405. PubMed ID: 32519518
[TBL] [Abstract][Full Text] [Related]
23. Anti-metabolic agent pegaspargase plus PD-1 antibody sintilimab for first-line treatment in advanced natural killer T cell lymphoma.
Xiong J; Cheng S; Gao X; Yu SH; Dai YT; Huang XY; Zhong HJ; Wang CF; Yi HM; Zhang H; Cao WG; Li R; Tang W; Zhao Y; Xu PP; Wang L; Zhao WL
Signal Transduct Target Ther; 2024 Mar; 9(1):62. PubMed ID: 38448403
[TBL] [Abstract][Full Text] [Related]
24. Efficacy and tolerance of pegaspargase-based chemotherapy in patients with nasal-type extranodal NK/T-cell lymphoma: a pilot study.
Wen JY; Li M; Li X; Chen J; Lin Q; Ma XK; Dong M; Wei L; Chen ZH; Wu XY
Asian Pac J Cancer Prev; 2014; 15(15):6275-81. PubMed ID: 25124611
[TBL] [Abstract][Full Text] [Related]
25. Circulating Low Absolute CD4+ T Cell Counts May Predict Poor Prognosis in Extranodal NK/T-Cell Lymphoma Patients Treating with Pegaspargase-Based Chemotherapy.
Zhang YP; Zhang R; Zhu HY; Wang L; Wu YJ; Liang JH; Shi WY; Liu H; Xu W; Li JY
Cancer Res Treat; 2019 Jan; 51(1):368-377. PubMed ID: 29764116
[TBL] [Abstract][Full Text] [Related]
26. Phase 2 trial of "sandwich" L-asparaginase, vincristine, and prednisone chemotherapy with radiotherapy in newly diagnosed, stage IE to IIE, nasal type, extranodal natural killer/T-cell lymphoma.
Jiang M; Zhang H; Jiang Y; Yang Q; Xie L; Liu W; Zhang W; Ji X; Li P; Chen N; Zhao S; Wang F; Zou L
Cancer; 2012 Jul; 118(13):3294-301. PubMed ID: 22139825
[TBL] [Abstract][Full Text] [Related]
27. Outcomes of patients treated with SVILE
Wei L; Yang L; Ye J; Cong J; Li X; Yao N; Yang J; Cui X; Ding J; Wu Y; Wang J
Cancer Biol Med; 2020 Aug; 17(3):795-804. PubMed ID: 32944407
[No Abstract] [Full Text] [Related]
28. A five
Vittayawacharin P; Khuhapinant A
Hematology; 2021 Dec; 26(1):75-82. PubMed ID: 33427594
[TBL] [Abstract][Full Text] [Related]
29. Pegylated asparaginase in feline high-grade lymphoma: clinical results of single injection and continued incorporation into a modified COP regimen.
Krupa A; de Vos J; Van Eetvelde L; Teske E
J Feline Med Surg; 2022 Aug; 24(8):e203-e213. PubMed ID: 35748790
[TBL] [Abstract][Full Text] [Related]
30. GELAD chemotherapy with sandwiched radiotherapy for patients with newly diagnosed stage IE/IIE natural killer/T-cell lymphoma: a prospective multicentre study.
Zhu Y; Tian S; Xu L; Ma Y; Zhang W; Wang L; Jin L; Liu C; Zhu C; Li Z; Hao S; Zhong H; Ding H; Tao R
Br J Haematol; 2022 Feb; 196(4):939-946. PubMed ID: 34806163
[TBL] [Abstract][Full Text] [Related]
31. Combined chemoradiation for the management of nasal natural killer (NK)/T-cell lymphoma: elucidating the significance of systemic chemotherapy.
Guo Y; Lu JJ; Ma X; Wang B; Hong X; Li X; Li J
Oral Oncol; 2008 Jan; 44(1):23-30. PubMed ID: 17306611
[TBL] [Abstract][Full Text] [Related]
32. Radiotherapy improves survival in early stage extranodal natural killer/T cell lymphoma patients receiving asparaginase-based chemotherapy.
Li YY; Feng LL; Niu SQ; Wang HY; Zhang LL; Wang L; Xia ZJ; Huang HQ; Xia YF; Zhang YJ; Wang XC
Oncotarget; 2017 Feb; 8(7):11480-11488. PubMed ID: 28002792
[TBL] [Abstract][Full Text] [Related]
33. Pegaspargase, gemcitabine, dexamethasone, and cisplatin (P-GDP) combined chemotherapy is effective for newly diagnosed extranodal NK/T-cell lymphoma: a retrospective study.
Liu T; Zhu F; Xiao Y; Li Q; Liu X; Yang K; Wu G; Zhang L
Cancer Manag Res; 2018; 10():5061-5069. PubMed ID: 30464606
[TBL] [Abstract][Full Text] [Related]
34. Efficacy of pegaspargase in extra nodal natural killer/T-cell lymphoma nasal type: A case report from China.
Xiong X; Cai Z; Yang J; Shu X
J Cancer Res Ther; 2015; 11(3):665. PubMed ID: 26458696
[TBL] [Abstract][Full Text] [Related]
35. A phase 2 study of methotrexate, etoposide, dexamethasone, and pegaspargase chemotherapy for newly diagnosed, relapsed, or refractory extranodal natural killer/T-cell lymphoma, nasal type: a multicenter trial in Northwest China.
Liang R; Gao GX; Chen JP; Wang JS; Wang XM; Zeng Y; Bai QX; Zhang T; Yang L; Dong BX; Gu HT; Shu MM; Hao CX; Wang JH; Zhang N; Chen XQ
Hematol Oncol; 2017 Dec; 35(4):619-629. PubMed ID: 27723108
[TBL] [Abstract][Full Text] [Related]
36. Combined immune checkpoint blockade and radiotherapy induces durable remission in relapsed natural killer/T-cell lymphoma: a case report and review of the literature.
McGehee E; Patel H; Pearson C; Clements K; Jaso JM; Chen W; Callan A; Desai N; Ramakrishnan Geethakumari P
J Med Case Rep; 2021 Apr; 15(1):221. PubMed ID: 33926575
[TBL] [Abstract][Full Text] [Related]
37. Comparative Study of L-Asparaginase-Based LOP Regimen Over CHOP Regimen Before Radiotherapy for Stage IIE Extranodal Nasal Type NK/T Cell Lymphoma: A Study of 2 Centers.
Huang L; Yuan B; Wu H; Chu H; Liu Y; Wu S; Li H; Lu H; Chen H
Clin Lymphoma Myeloma Leuk; 2017 Mar; 17(3):152-158. PubMed ID: 28215935
[TBL] [Abstract][Full Text] [Related]
38. Short-Course Versus Long-Course Chemoradiotherapy for Stage IE-IIE Extranodal Natural Killer/T cell Lymphoma, Nasal Type: A Multicenter Retrospective Study.
Li J; Li Y; Zhong M; Liu X; Song Y; Li J; Li K; Yi P
Med Sci Monit; 2018 May; 24():2683-2692. PubMed ID: 29712887
[TBL] [Abstract][Full Text] [Related]
39. Concurrent chemoradiotherapy followed by L-asparaginase-containing chemotherapy, VIDL, for localized nasal extranodal NK/T cell lymphoma: CISL08-01 phase II study.
Kim SJ; Yang DH; Kim JS; Kwak JY; Eom HS; Hong DS; Won JH; Lee JH; Yoon DH; Cho J; Nam TK; Lee SW; Ahn YC; Suh C; Kim WS
Ann Hematol; 2014 Nov; 93(11):1895-901. PubMed ID: 24947798
[TBL] [Abstract][Full Text] [Related]
40. Utility of baseline, interim and end-of-treatment
Chang Y; Fu X; Sun Z; Xie X; Wang R; Li Z; Zhang X; Sheng G; Zhang M
Sci Rep; 2017 Jan; 7():41057. PubMed ID: 28117395
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
